Merck & Co. Inc.

MRK13 Dec 2024
Healthcare
$102.61
+0.02 (+1.53%)
Lowest Today
$100.12
Highest Today
$102.96
Today’s Open
$102.61
Prev. Close
$99.75
52 Week High
$133.74
52 Week Low
$94.48
To Invest in Merck & Co. Inc.

Merck & Co. Inc.

Healthcare
MRK13 Dec 2024
+0.02 (+1.53%)
1M
3M
6M
1Y
5Y
Low
$100.12
Day’s Range
High
$102.96
100.12
52 Week Low
$94.48
52-Week Range
52 Week High
$133.74
94.48
1 Day
-
1 Week
-3.7%
1 month return
+1.23%
3 month return
-13.46%
6 month return
-23.37%
1 Year return
-4.4%
3 Years return
+35.9%
5 Years return
+16.86%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
9.88
BlackRock Inc
8.19
State Street Corp
4.71
Vanguard Total Stock Mkt Idx Inv
3.16
Wellington Management Company LLP
3
Vanguard Institutional 500 Index Trust
2.66
Geode Capital Management, LLC
2.34

Market Status

Fundamentals
Market Cap
262550.52 mln
PB Ratio
5.9
PE Ratio
21.13
Enterprise Value
286088.88 mln
Total Assets
106675 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and  commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Organisation
Merck & Co. Inc.
Employees
70000
Industry
Drug Manufacturers - General
CEO
Mr. Robert M. Davis J.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step